We are live on ! Find out more
PBAXU

Phoenix Biotech Acquisition Corp. Unit
PBAXU

Delisted

PBAXU was delisted on the 7th of February, 2024.

Back to rankings

3 hedge funds and large institutions have $1.14M invested in Phoenix Biotech Acquisition Corp. Unit in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% less funds holding

Funds holding: 21 → 3 (-18)

95% less capital invested

Capital invested by funds: $21.1M → $1.14M (-$20M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 18

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
-18
Holders Change %
-85.71%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SCM
Shaolin Capital Management
Florida
-$7.57M
2
CCA
Castle Creek Arbitrage
Colorado
-$4.04M
3
WC
Wealthspring Capital
New York
-$1.79M
4
WCMNY
Westchester Capital Management (New York)
New York
-$1.52M
5
SIA
Schechter Investment Advisors
Michigan
-$1.51M

PBAXU Hedge Fund Activity: Q4 2022 in Review

3 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Phoenix Biotech Acquisition Corp. Unit (PBAXU) for Q4 2022, worth a combined $1.14M — down 95% from $21.1M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of PBAXU and 0 opened new positions — a net loss of 18 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Shaolin Capital Management, exiting entirely with an estimated $7.57M sold.

  • 3 institutional investors held Phoenix Biotech Acquisition Corp. Unit (PBAXU) as of Q4 2022, down from 21 in Q3 2022.
  • Funds reported $1.14M of Phoenix Biotech Acquisition Corp. Unit stock for Q4 2022, down 95% quarter-over-quarter.
  • 0 funds opened new Phoenix Biotech Acquisition Corp. Unit positions in Q4 2022 and 18 closed out, a net change of -18 holders.
  • The largest Phoenix Biotech Acquisition Corp. Unit seller in Q4 2022 was Shaolin Capital Management, an estimated $7.57M sold.

Based on aggregated 13F filings for Q4 2022.